Prothea Secures $13 Million to Progress Cancer Therapeutics

Prothea Technologies has secured €12 million in an early-stage funding round to progress cancer diagnostics and treatments.  

The organisation seeks to progress technologies for managing cancer. This includes creating tools to reduce inaccurate tissue samples and increase treatment options for small tumours.  

The early-stage investors were Earlybird Venture Capital and Mérieux Equity Partner.  

The funds will go towards advancing Prothea’s cancer medical systems, including a microendoscope integrated with an image processing platform.  

Prothea also aims to initiate clinical trials for cancer imaging and tissue sampling for the treatment of lung cancer using the financing.  

The organisation has goals to merge imaging and ablation techniques to decrease time spent at medical clinics. 

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.